.Attribute Medication, Posted online: 09 Oct 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec got FDA permission after an unfavorable trial, which highlights the numerous complications as well as challenges of drug progression within this environment.